Sven Ante  Lundberg net worth and biography

Sven Lundberg Biography and Net Worth

President, Chief Executive Officer, Executive Director of Merus
Bill Lundberg, M.D. has served as a non-­executive director of our board of directors from June 2019 to December 2019, and as an executive director since December 2019. Since December 2019, Dr. Lundberg has served as our President and Chief Executive Officer. From January 2015 to February 2018, Dr. Lundberg was Chief Scientific Officer of CRISPR Therapeutics AG (CRISPR), a biotechnology company, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. From February 2011 to January 2015, Dr. Lundberg was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (Alexion), where he oversaw research and development from discovery through early-stage development, and prior to that, he was Director and Chief Medical Officer of Taligen Therapeutics, Inc. (Taligen), a biotechnology company, which was acquired by Alexion in 2011. Prior to Taligen, he held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Antisoma, Wyeth (now Pfizer), and Genzyme. Dr. Lundberg currently serves on the board of directors of the publicly traded life science company Vor Biopharma and Q32 Bio. Dr. Lundberg received an M.D. from Stanford University and M.B.A. from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/M.I.T., and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute.

What is Sven Ante Lundberg's net worth?

The estimated net worth of Sven Ante Lundberg is at least $2.21 million as of November 3rd, 2022. Dr. Lundberg owns 40,576 shares of Merus stock worth more than $2,211,392 as of November 8th. This net worth evaluation does not reflect any other assets that Dr. Lundberg may own. Additionally, Dr. Lundberg receives a salary of $953,060.00 as President, Chief Executive Officer, Executive Director at Merus. Learn More about Sven Ante Lundberg's net worth.

How old is Sven Ante Lundberg?

Dr. Lundberg is currently 61 years old. There are 5 older executives and no younger executives at Merus. Learn More on Sven Ante Lundberg's age.

What is Sven Ante Lundberg's salary?

As the President, Chief Executive Officer, Executive Director of Merus, Dr. Lundberg earns $953,060.00 per year. Learn More on Sven Ante Lundberg's salary.

How do I contact Sven Ante Lundberg?

The corporate mailing address for Dr. Lundberg and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Sven Ante Lundberg's contact information.

Has Sven Ante Lundberg been buying or selling shares of Merus?

Sven Ante Lundberg has not been actively trading shares of Merus in the last ninety days. Most recently, on Thursday, November 3rd, Sven Ante Lundberg bought 14,706 shares of Merus stock. The stock was acquired at an average cost of $14.38 per share, with a total value of $211,472.28. Following the completion of the transaction, the chief executive officer now directly owns 40,576 shares of the company's stock, valued at $583,482.88. Learn More on Sven Ante Lundberg's trading history.

Who are Merus' active insiders?

Merus' insider roster includes Lex Bakker (SVP), Kruif de Kruif (SVP), Sven Lundberg (President, Chief Executive Officer, Executive Director), and Peter Silverman (EVP, Chief Operating Officer, & General Counsel). Learn More on Merus' active insiders.

Are insiders buying or selling shares of Merus?

In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 47,376 shares worth more than $1,969,643.70. The most recent insider tranaction occured on June, 27th when COO Peter B. Silverman sold 10,000 shares worth more than $600,000.00. Insiders at Merus own 4.6% of the company. Learn More about insider trades at Merus.

Information on this page was last updated on 6/27/2024.

Sven Ante Lundberg Insider Trading History at Merus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2022Buy14,706$14.38$211,472.2840,576View SEC Filing Icon  
8/22/2022Buy5,826$22.92$133,531.9225,870View SEC Filing Icon  
8/19/2022Buy704$22.99$16,184.9620,044View SEC Filing Icon  
7/12/2022Buy4,340$22.97$99,689.8019,340View SEC Filing Icon  
See Full Table

Sven Ante Lundberg Buying and Selling Activity at Merus

This chart shows Sven Ante Lundberg's buying and selling at Merus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merus Company Overview

Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $54.50
Low: $53.50
High: $54.90

50 Day Range

MA: $50.92
Low: $47.19
High: $54.50

2 Week Range

Now: $54.50
Low: $22.01
High: $61.61

Volume

340,271 shs

Average Volume

688,089 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12